TNF Pharmaceuticals Inc
TNFA5.200USD
0.000
Close 12/22, 16:00（ET）Quotes delayed by 15 min
152.80MMarket Cap
LossP/E TTM
More Details of TNF Pharmaceuticals Inc Company
TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on developing novel therapies for age-related diseases and autoimmune and inflammatory conditions. It is focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets: MYMD-1 and Supera-CBD. MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. Supera-CBD is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the growing CBD market, which includes both Food and Drug Administration (FDA) approved drugs and CBD products not currently regulated as drugs.
TNF Pharmaceuticals Inc Info
Ticker SymbolTNFA
Company nameTNF Pharmaceuticals Inc
IPO dateJul 24, 2008
CEO- -
Number of employees2
Security typeOrdinary Share
Fiscal year-endJul 24
Address1185 Avenue Of The Americas
CityNEW YORK
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code10036
Phone18568488698
Websitehttps://tnfpharma.com/
Ticker SymbolTNFA
IPO dateJul 24, 2008
CEO- -
Company Executives of TNF Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Stephen Friscia
Mr. Stephen Friscia
Independent Director
Independent Director
27.16K
+528.44%
Dr. Mitchell Glass, M.D.
Dr. Mitchell Glass, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
13.58K
+528.70%
Mr. Christopher C. Schreiber
Mr. Christopher C. Schreiber
Director
Director
30.00
+3.45%
Mr. Robert Schatz
Mr. Robert Schatz
Investor Relations
Investor Relations
--
--
Mr. Bill Joe White
Mr. Bill Joe White
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ian Rhodes
Mr. Ian Rhodes
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Bruce Bernstein
Mr. Bruce Bernstein
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Stephen Friscia
Mr. Stephen Friscia
Independent Director
Independent Director
27.16K
+528.44%
Dr. Mitchell Glass, M.D.
Dr. Mitchell Glass, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
13.58K
+528.70%
Mr. Christopher C. Schreiber
Mr. Christopher C. Schreiber
Director
Director
30.00
+3.45%
Mr. Robert Schatz
Mr. Robert Schatz
Investor Relations
Investor Relations
--
--
Mr. Bill Joe White
Mr. Bill Joe White
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Revenue Breakdown
Currency: USDUpdated: Wed, Mar 5
Currency: USDUpdated: Wed, Mar 5
FY2019
By BusinessUSD
Name
Revenue
Proportion
Particle ImmunoFiltration Assay (“PIFA”)
1.33M
84.19%
MicroParticle Catalyzed Biosensor (“MPC”)
126.15K
8.00%
Rapid Enzymatic Assay (“REA”)
85.00K
5.39%
Other
38.13K
2.42%
By RegionUSD
Name
Revenue
Proportion
United States
1.56M
98.89%
Rest of the World
17.50K
1.11%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Particle ImmunoFiltration Assay (“PIFA”)
1.33M
84.19%
MicroParticle Catalyzed Biosensor (“MPC”)
126.15K
8.00%
Rapid Enzymatic Assay (“REA”)
85.00K
5.39%
Other
38.13K
2.42%
Shareholding Stats
Updated: Fri, Nov 21
Updated: Fri, Nov 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Silverman (Joshua)
2.61%
White (Billy Joe)
0.65%
Friscia (Stephen)
0.65%
Bernstein Bruce G
0.60%
Glass (Mitchell)
0.33%
Other
95.16%
Shareholders
Shareholders
Proportion
Silverman (Joshua)
2.61%
White (Billy Joe)
0.65%
Friscia (Stephen)
0.65%
Bernstein Bruce G
0.60%
Glass (Mitchell)
0.33%
Other
95.16%
Shareholder Types
Shareholders
Proportion
Individual Investor
5.14%
Investment Advisor
0.37%
Investment Advisor/Hedge Fund
0.14%
Hedge Fund
0.04%
Other
94.31%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
75
5.05K
0.30%
-6.50K
2025Q2
99
215.39K
1.52%
-914.94K
2025Q1
104
502.79K
11.97%
-596.97K
2024Q4
102
433.19K
15.72%
-602.18K
2024Q3
106
197.10K
7.58%
-978.19K
2024Q2
105
1.10M
49.30%
+712.56K
2024Q1
107
1.15M
55.47%
+708.08K
2023Q4
110
433.69K
29.01%
+147.72K
2023Q3
111
383.85K
27.97%
-36.08K
2023Q2
105
390.25K
29.44%
-23.03K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Silverman (Joshua)
30.00
0.03%
--
--
Apr 04, 2025
White (Billy Joe)
25.00
0.02%
--
--
Apr 04, 2025
UBS Financial Services, Inc.
650.00
0.04%
+650.00
--
Jun 30, 2025
Tower Research Capital LLC
50.00
0%
-1.00
-1.96%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
Cambria Cannabis ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proportion0%
Cambria Cannabis ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 13, 2024
Merger
30→1
Feb 13, 2024
Merger
30→1
Feb 13, 2024
Merger
30→1
Feb 13, 2024
Merger
30→1
Apr 16, 2021
Merger
2→1
Apr 16, 2021
Merger
2→1
Date
Type
Ratio
Feb 13, 2024
Merger
30→1
Feb 13, 2024
Merger
30→1
Feb 13, 2024
Merger
30→1
Feb 13, 2024
Merger
30→1
Apr 16, 2021
Merger
2→1
Apr 16, 2021
Merger
2→1
Apr 16, 2021
Merger
2→1
Apr 16, 2021
Merger
2→1
FAQs
Who are the top five shareholders of TNF Pharmaceuticals Inc?
The top five shareholders of TNF Pharmaceuticals Inc are:
Silverman (Joshua) holds 30.00 shares, accounting for 0.03% of the total shares.
White (Billy Joe) holds 25.00 shares, accounting for 0.02% of the total shares.
UBS Financial Services, Inc. holds 650.00 shares, accounting for 0.04% of the total shares.
Tower Research Capital LLC holds 50.00 shares, accounting for 0.00% of the total shares.
Silverman (Joshua) holds 30.00 shares, accounting for 0.03% of the total shares.
White (Billy Joe) holds 25.00 shares, accounting for 0.02% of the total shares.
UBS Financial Services, Inc. holds 650.00 shares, accounting for 0.04% of the total shares.
Tower Research Capital LLC holds 50.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of TNF Pharmaceuticals Inc?
The top three shareholder types of TNF Pharmaceuticals Inc are:
Silverman (Joshua)
White (Billy Joe)
Friscia (Stephen)
Silverman (Joshua)
White (Billy Joe)
Friscia (Stephen)
How many institutions hold shares of TNF Pharmaceuticals Inc (TNFA)?
As of 2025Q3, 75 institutions hold shares of TNF Pharmaceuticals Inc, with a combined market value of approximately 5.05K, accounting for 0.30% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -1.21%.
What is the biggest source of revenue for TNF Pharmaceuticals Inc?
In FY2019, the Particle ImmunoFiltration Assay (“PIFA”) business generated the highest revenue for TNF Pharmaceuticals Inc, amounting to 1.33M and accounting for 84.19% of total revenue.
